This pilot study evaluates the feasibility of identifying biomarker enrichment retrospectively, acquiring tumor for HER2 expression as a sufficiently discriminating biomarker in adenocarcinomas of the uterine cervix against other cell types, prior to launching a phase 0 trial investigating state-of-the-art molecular profiles as possible explanations for treatment response (NCT05462951). The gene discussed is ERBB2; the disease is adenocarcinoma.